Market Overview

UPDATE: Bank of America Merrill Lynch Reiterates Buy Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Lilly Issues Update on Evacetrapib Phase 3 Trial: Last Patient Visit in ACCELERATE Expecting Jul. '16
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Premarket Biotech Digest: Merck Earnings, Gilead Beats Again, NantKwest Surges (Seeking Alpha)

In a report published Wednesday, Bank of America Merrill Lynch reiterated its Buy rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $57.00 to $60.00.

BofA Merrill Lynch noted, “LLY offers a good mix of compelling valuation, an attractive dividend yield with a track record of returning cash to shareholders, and pipeline optionality. Several promising late-stage pipeline assets are underappreciated, in our view, and could be transformative to LLYs growth trajectory (ramucirumab, solanezumab and the four Phase III diabetes assets - two basal insulins, empagliflozin and dulaglutide).”

Eli Lilly & Co. closed on Tuesday at $51.88.

Latest Ratings for LLY

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jul 2015SunTrust Robinson HumphreyMaintainsBuy
Jul 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill LynchAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Get Benzinga's Newsletters